Inventiva Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Inventiva (EPA:IVA) Full Year 2024 Results

Key Financial Results

• Revenue: €14.7m (down 36% from FY 2023).
• Net loss: €184.2m (loss widened by 67% from FY 2023).
• €3.08 loss per share (further deteriorated from €2.44 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Inventiva Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) missed analyst estimates by 153%.

Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Inventiva (of which 2 are concerning!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.